Arcus Biosciences rises on results from domvanalimab cancer study

[Cancer Anatomy]
wildpixel/iStock via Getty Images

* Arcus Biosciences (NYSE:RCUS [https://seekingalpha.com/symbol/RCUS]) rose after it reported results from mid-stage study of its monoclinical antibody domvanalimab with zimberelimab and chemotherapy in patients with gastric, gastroesophageal junction or esophageal adenocarcinoma.
* The stock is up 7.5% today.
* The study shows a median overall survival of 26.7 months and a median progression-free survival of 12.9 months, with an objective response rate of 59%.
* As of the data cut-off, immune-mediated treatment-emergent adverse events attributed to domvanalimab and/or zimberelimab were reported [https://seekingalpha.com/pr/20262748-anti-tigit-domvanalimab-plus-anti-pdminus-1-zimberelimab-and-chemotherapy-showed-26_7-months]in nine patients, while infusion-related reactions occurred in three patients.

MORE ON ARCUS BIOSCIENCES

* Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call Transcript [https://seekingalpha.com/article/4828158-arcus-biosciences-inc-rcus-shareholder-analyst-call-transcript]
* Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call - Slideshow [https://seekingalpha.com/article/4828119-arcus-biosciences-inc-rcus-shareholder-analyst-call-slideshow]
* Arcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript [https://seekingalpha.com/article/4821532-arcus-biosciences-inc-rcus-presents-at-morgan-stanley-23rd-annual-global-healthcare]
* Arcus Biosciences Q2 2025 Earnings Preview [https://seekingalpha.com/news/4478725-arcus-biosciences-q2-2025-earnings-preview]
* Seeking Alpha’s Quant Rating on Arcus Biosciences [https://seekingalpha.com/symbol/RCUS/ratings/quant-ratings]